5-Amino-1MQ
5-Amino-1MQ isn’t a peptide — it’s a small molecule that blocks a specific enzyme involved in fat storage. Here’s what the (entirely preclinical) research shows.
Every compound in our catalog is backed by published research — some of it decades old, some of it published this year. This section is where we break that research down in plain language, one compound at a time: what’s been studied, what the findings actually show, and where you can go to read the original source yourself.
We keep this section grounded in what the published literature actually says — not marketing claims, not anecdote. Where the research is early-stage or limited to animal models, we say so.
5-Amino-1MQ isn’t a peptide — it’s a small molecule that blocks a specific enzyme involved in fat storage. Here’s what the (entirely preclinical) research shows.
AOD-9604 reached six human trials — more than most compounds here — but its efficacy claims were never actually published in peer-reviewed form. Here’s the real story behind the numbers.
BPC-157 has become one of the most studied peptides in preclinical tissue-repair research. We break down what the tendon, ligament, and gastrointestinal research actually shows — and where you can read the original studies yourself.
TB-500 shares its research lineage with Thymosin Beta-4 — including some of the most notable cardiovascular regeneration studies in peptide science. We break down what that body of evidence supports.
GHK-Cu has over four decades of research behind it, but the human data remains early-stage pilot work — not the large trials some marketing suggests. Here’s the real evidence.
Glow Blend combines BPC-157, TB-500, and GHK-Cu on the theory that each targets a different stage of tissue repair. Here’s what’s actually been tested — and what hasn’t.
Melanotan II’s early trials led researchers somewhere unexpected — and its tanning use still lacks the large trial data its other effects have. Here’s the fuller picture.
MOTS-C is a mitochondria-encoded peptide tied to metabolism and exercise physiology. Here’s what the research shows — including a rare human exercise-response finding.
NAD+ levels decline sharply with age — but the research behind boosting them is more complicated than most marketing suggests.
Retatrutide is the first triple-hormone agonist to reach late-stage human trials, with some of the largest weight-loss results reported to date. Here’s what the trials found, and how close it is to approval.
Selank’s research history spans anxiety behavior, memory protection, and gene expression — mostly from Russian and preclinical rodent studies. Here’s what that evidence actually covers.
Semaglutide’s clinical trial program spans diabetes and weight management alike. Here’s what the SUSTAIN and STEP trials actually found — and how it stacks up against similar therapies.
Semax holds a rare distinction among research peptides: actual regulatory approval, just not from the FDA. Here’s what the BDNF and neuroprotection research shows.
Sermorelin works upstream of growth hormone itself, prompting the body’s own pituitary to release it. Here’s what decades of aging and endocrinology research actually show.
TB-500 shares its research lineage with Thymosin Beta-4 — including some of the most notable cardiovascular regeneration studies in peptide science. Here’s what that evidence actually shows.
Tesamorelin carries a narrow but real FDA approval — and one of the most rigorous clinical trial programs of any peptide in this category. Here’s what the data shows.
Tirzepatide’s dual-hormone mechanism has driven some of the largest clinical trials in this category. Here’s what the glycemic control and weight management research actually found.
BPC-157 and TB-500 are frequently paired in peptide research under the name ‘Wolverine Blend.’ Here’s what’s actually been studied on each compound — and where the evidence stands.
You must be at least 21 years of age to access Core Molecular Solutions. By entering this site, you confirm that you meet this requirement